OBJECTIVE： To investigate the clinical efficacy and safety of recombinant human epidermal growth factor （rhEGF） combined with lipoic acid in the treatment of diabetic foot. METHODS： A total of 68 patients with diabetic foot were randomly divided into observation group and control group with 34 cases in each group. Both groups were given conventional therapy and Lipolic acid injection 0.6 ml added into Sodium chloride injection 250 ml. ivgtt （protecting form light）， qd； observation group was additionally given rhEGF for external use 1 ml and vaseline on the wounds， gauze dressing， qd. Treatment course of 2 groups lasted for 7 d. Clinical efficacy， ulcer area， the expression of Bcl-2 and Bax were compared between 2 groups as well as the occurrence of ADR. RESULTS： The total effective rate of observation group （94.1％） was significantly higher than that of control group （67.6％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in ulcer area， the levels of Bcl-2 and Bax between 2 groups （P＞0.05）. After treatment， ulcer area decreased significantly，  the level of Bcl-2 increased significantly in 2 groups， while the level of Bax decreased significantly； the improvement of observation group was more significant than that of control group， with statistical significance （P＜0.05）.  There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）.  CONCLUSIONS： rhEGF combined with lipoic acid is effective for diabetic foot with good safety.